Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,508 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Brain Injury, Craniocerebral Trauma
Interventions: cosyntropin, metyrapone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 20 Years to 35 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions: filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 244
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Solid Tumor, Unspecified, Adult
Interventions: Determination of ATM alteration status.; Other
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Vasopressin, Arginine, ADH, Placebo; Sterile Saline; Drug
Lead sponsor: Bowdoin College; Other
Eligibility: 18 Years to 30 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: InFertility
Interventions: Pulsatile gonadotropin-releasing hormone (GnRH), Clomiphene Citrate, Placebo Pulsatile GnRH, Placebo Clomiphene Citrate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Prostate Cancer, Stage IV Prostate Cancer
Interventions: Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel, Tislelizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo, Liraglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland

Conditions: Pancreatitis, Diabetes Mellitus
Interventions: Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin; Diagnostic Test · Genetic · Other + 1 more
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 21 Years
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon

Conditions: Lymphoma, Disorder Related to Bone Marrow Transplantation
Interventions: Fludarabine, Melphalan, Allogeneic Transplant, Thymoglobulin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Efprezimod alfa, Saline; Biological · Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Spinal Cord Injury, Pain
Interventions: botulinum toxin A, placebo; Drug · Other
Lead sponsor: Craig Hospital; Other
Eligibility: 15 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Tadalafil, Placebo, Saline load; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypothyroidism
Interventions: L-thyroxine (L-T4); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pain
Interventions: Botulinum Toxin A, Placebo - Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Soft Tissue Sarcoma
Interventions: Combination Radiation, Immunotherapy, Surgery; Combination Product
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: PCOS
Interventions: Dexamethasone, recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetic Foot Ulcer
Interventions: PEP (Purified Exosome Product) / TISSEEL; Biological
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: Healthy
Interventions: rLP2086, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 25 Years
Enrollment: 3,301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more

Conditions: Dysbiosis
Interventions: Goya Foods - Canned Chickpeas, Goya Foods - Canned Lentils, Control; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Search by objective public record fields.

Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Vasopressin Effects on Human Social Communication

Angiotensin 2 for AKI After OLT

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

A Study of Tirzepatide in Overweight and Very Overweight Participants

Imaging Biomarkers of Pancreatic Function and Disease

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

Neurocognitive and Metabolic Effects of Mild Hypothyroidism

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health